Back to Browse Journals » Open Access Rheumatology: Research and Reviews » Volume 4

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Authors Murakami M, Tomiita M, Nishimoto N

Published Date July 2012 Volume 2012:4 Pages 71—79

DOI http://dx.doi.org/10.2147/OARRR.S21969

Received 11 February 2012, Accepted 21 March 2012, Published 5 July 2012

Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto1
1Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan

Abstract: Systemic juvenile idiopathic arthritis is one of the common rheumatic diseases in childhood and characterized by spiking fever, evanescent skin rash, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. Children with systemic juvenile idiopathic arthritis often show growth retardation and developmental abnormality, as well as macrophage activation syndrome, a life-threatening complication. Overproduction of interleukin-6 is pathologically responsible for the systemic inflammatory manifestations and abnormal laboratory results with systemic juvenile idiopathic arthritis. Thus, tocilizumab, a humanized antihuman interleukin-6 receptor antibody, has been developed as a therapeutic agent for the disease. A series of clinical studies have demonstrated the excellent efficacy and safety of tocilizumab for patients with active disease. Tocilizumab was approved for systemic juvenile idiopathic arthritis in Japan in 2008 and in the European Union and the United States in 2011.

Keywords: systemic juvenile idiopathic arthritis, tocilizumab, antihuman interleukin-6 receptor antibody, biologics

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Visual fields in a chloroquine treatment

García-Domene MC, Díez-Ajenjo MA, de Fez MD, Luque MJ

Clinical Optometry 2014, 6:59-70

Published Date: 30 September 2014

Visual performance and aberration associated with contact lens wear in patients with keratoconus: a pilot study

Abdu M, Mohidin N, Mohd-Ali B

Clinical Optometry 2014, 6:47-57

Published Date: 16 August 2014

Differences in daily disposable circle lens performance characteristics

Schafer JM, Reindel WT, Rah MJ, Chan O, Zhang L

Clinical Optometry 2014, 6:37-42

Published Date: 3 April 2014

Reinventing your primary care practice: becoming an MDCEO™

Conard SE, Courtney MR

Journal of Healthcare Leadership 2013, 5:1-8

Published Date: 7 March 2013

The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals

Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL

International Journal of Nanomedicine 2011, 6:3125-3137

Published Date: 2 December 2011

Tackling obesity: new therapeutic agents for assisted weight loss

JG Karam, SI McFarlane

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010, 3:95-112

Published Date: 26 April 2010